Uncategorized

AlgoTx Raises €20M to Conduct ATX01’s Phase 2 Program in Peripheral Neuropathic Pain

European biotech AlgoTx, the developer of first-in-class treatment ATX01 for chemotherapy-induced peripheral neuropathy, announced the success of a €20M Series B fundraising led by Relyens Innovation Santé / Turenne Capital, followed by UI Investissement, and historical investors Bpifrance through its Innobio 2 fund and Omnes Capital.

AlgoTx Raises €20M to Conduct ATX01’s Phase 2 Program in Peripheral Neuropathic Pain Read More »

Innovation in Resistance Management: VECTRONTM T500, a New Vector Control Product, is Prequalified by the World Health Organization (WHO)

VECTRONTM T500 is a new IRS product containing TENEBENALTM, the world’s first meta-diamide active ingredient developed by Mitsui Chemicals Agro which has a different mode of action from existing vector control products.

Innovation in Resistance Management: VECTRONTM T500, a New Vector Control Product, is Prequalified by the World Health Organization (WHO) Read More »

Scroll to Top